Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 11.26%, which has investors questioning if this is right time ...

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed ...

Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $0.96 which represents a decrease of $-0.03 or -3.03% from the prior close of $0.99. The stock opened at $0.99 and touched a ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The event will be ...

Lexicon Pharmaceuticals ... the FDA did not change the PDUFA date for Zynquista. Shares of the company were up 13.7% on Aug ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company leveraging advanced genetic research to develop transformative medicines, particularly for diabetes and related conditions.

Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $0.99 which represents a slight increase of $0.10 or 11.24% from the prior close of $0.89. The stock opened at $0.97 and ...

Stay informed and make judicious decisions using our Ratings Table. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization ...

Lexicon Pharmaceuticals received a complete ... was expected and aligns with the pharmaceutical company's previously disclosed decision to discontinue the treatment and focus solely on its ...